Join

Compare · EOG vs PRTG

EOG vs PRTG

Side-by-side comparison of EOG Resources Inc. (EOG) and Portage Biotech Inc. (PRTG): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both EOG and PRTG operate in Oil & Gas Production (Energy), so they compete in similar markets.
  • EOG is the larger of the two at $75.37B, about 613.9x PRTG ($122.8M).
  • EOG has hit the wire 15 times in the past 4 weeks while PRTG has been quiet.
  • EOG has more recent analyst coverage (25 ratings vs 5 for PRTG).
MetricEOGPRTG
Company
EOG Resources Inc.
Portage Biotech Inc.
Price
-
-
Market cap
$75.37B
$122.8M
1M return
-
-
1Y return
-
-
Industry
Oil & Gas Production
Oil & Gas Production
Exchange
NYSE
NASDAQ
IPO
News (4w)
15
0
Recent ratings
25
5
EOG

EOG Resources Inc.

EOG Resources, Inc., together with its subsidiaries, explores for, develops, produces, and markets crude oil, and natural gas and natural gas liquids. Its principal producing areas are in New Mexico and Texas in the United States; the Republic of Trinidad and Tobago; the People's Republic of China; and the Sultanate of Oman. As of December 31, 2020, it had total estimated net proved reserves of 3,220 million barrels of oil equivalent, including 1,514 million barrels (MMBbl) of crude oil and condensate reserves; 813 MMBbl of natural gas liquid reserves; and 5,360 billion cubic feet of natural gas reserves. The company was formerly known as Enron Oil & Gas Company. EOG Resources, Inc. was incorporated in 1985 and is headquartered in Houston, Texas.

PRTG

Portage Biotech Inc.

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

Latest EOG

Latest PRTG